Quetiapine augmentation in depressed patients with partial response to antidepressants
James S Olver, Sophie Ignatiadis, Paul Maruff, Graham D Burrows, Trevor R Norman
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL | WILEY | Published : 2008
OBJECTIVE: Clinical trials suggest between 30-50% of depressed patients have an inadequate outcome to antidepressant pharmacotherapy. Among the approaches to improve outcome has been augmentation with antipsychotic medications. We aim to investigate the efficacy and tolerability of augmentation with quetiapine in depressed patients with a partial response to antidepressants. METHODS: Patients with a Major Depressive Disorder (DSMIV) who had partial/no response to a stable dose of an Selective Serotonin Reuptake Inhibitors (SSRI)/SNRI were recruited. All patients received add-on quetiapine (200-600 mg nocte) in a 6-week trial. Outcome measures (HAMD, MADRS) were assessed at screening, baselin..View full abstract
Awarded by Astrazeneca Pharmaceuticals
This study was funded by all Investigator Initiated Grant made available from Astrazeneca Pharmaceuticals (Protocol Number AU-SEA-0004).